INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SPPI

Group 1 - The class action lawsuit against Spectrum Pharmaceuticals, Inc. involves allegations of securities fraud and unlawful business practices by the company and certain officers or directors [2][4] - Investors have until September 24, 2025, to request appointment as Lead Plaintiff if they purchased Spectrum securities during the Class Period [2] - The lawsuit specifically addresses misleading statements made by Spectrum regarding its Pinnacle Study, a clinical trial for the drug poziotinib aimed at treating lung cancer patients [4] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for class members [5] - The firm has been active in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [5]